Patient Solutions (1-833-223-2428)
FATIGUE
CALCULATOR
How much are you impacted by fatigue?
When living with Cold Agglutinin Disease (CAD), it may feel as if the normal rhythm of your daily life has been disrupted. Chronic fatigue is frequently reported in patients with CAD and may impact you in a variety of ways, including affecting your physical health and daily routine.
I've experienced plenty of Cold Agglutinin Disease symptoms. There was a time when my fatigue was so bad I could not even walk to my mailbox, I'd be so out of breath.
—JOANN, LIVING WITH COLD AGGLUTININ DISEASE (CAD)
On average, how many days (0-7) per week are you impacted by fatigue in the following areas:
How much time does infusing with ENJAYMO take?
ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks thereafter.
Infusion with ENJAYMO usually takes 1 to 2 hours. After your first infusion, you will be monitored for up to 2 hours for possible infusion or allergic reactions. After all future infusions, you will be monitored for 1 hour. After your first 2 weeks of treatment, your infusions will occur every 2 weeks.†
1 day every 2 weeks
after starting on ENJAYMO
Following initiation, infusions should occur:
Addressing the impact of Cold Agglutinin Disease with ENJAYMO
If your body destroys red blood cells in a process called hemolysis, it can lead to anemia. Anemia and hemolysis are key contributors to fatigue in patients with Cold Agglutinin Disease. ENJAYMO helps reduce hemolysis in Cold Agglutinin Disease.
Significant improvement in fatigue at study end
Patients on ENJAYMO (n=22) over 26 weeks were asked about the impact of fatigue on a scale of 0 (not at all) to 4 (very much so) for a total of 52 points. This 13-item survey (FACIT-Fatigue) included questions about:
- How fatigued they felt
- Frustration because of tiredness
- Needing a nap to get through the day
- How weak and tired they felt
- Ability to do usual activities
In the clinical trial, patients received either ENJAYMO (n=22) or placebo for 26 weeks (6 months). Patients on ENJAYMO had an average 11-point improvement from baseline (improving from an average baseline score of 31.67 points to an average score at treatment assessment of 42.5 points) over 26 weeks vs a 2-point improvement in patients on placebo (n=20). Higher scores on the survey meant a person felt less fatigue.
When talking to your doctor about fatigue, make sure to use everyday examples. Chronic fatigue has a subtle way of inserting itself into life’s routine moments and can become easy to overlook.
Discover more about the impact ENJAYMO can have on your fatigue
In a clinical trial, patients on ENJAYMO saw an improvement in their feelings of fatigue.
What is ENJAYMO?
ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).
It is not known if ENJAYMO is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
- Serious Infections: ENJAYMO is a prescription medicine that affects your immune system. ENJAYMO may lower the ability of your immune system to fight infections. ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.
- You must complete or be up to date with the vaccines against Streptococcus pneumoniae and Neisseria meningitidis at least 2 weeks before your first dose of ENJAYMO.
- If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
- If you have been vaccinated against these bacteria in the past, you might need additional vaccines before starting ENJAYMO. Your healthcare provider will decide if you need additional vaccines.
- Vaccines do not prevent all infections caused by encapsulated bacteria. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a serious infection: fever with or without shivers or chills, fever with chest pain and cough, fever with high heart rate, headache and fever, confusion, clammy skin, fever and a rash, fever with breathlessness or fast breathing, headache with nausea or vomiting, headache with stiff neck or stiff back, body aches with flu-like symptoms, and/or eyes sensitive to light.
- Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including: shortness of breath, decrease in blood pressure, chest discomfort, rapid heartbeat, nausea, injection site reaction, flushing, headache, dizziness, rash, and itchy skin.
- Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including: joint pain or swelling, rash on the cheeks and nose, and unexplained fever.
- If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD to return. Symptoms or problems that can happen due to red blood cell breakdown include: tiredness, shortness of breath, rapid heart rate, and blood in your urine or dark urine.
The most common side effects of ENJAYMO include: increase in blood pressure, urinary tract infection, respiratory tract infection, bacterial infection, swelling in lower legs or hands, joint pain, headache, nausea, runny nose, bluish color to the lips and skin, dizziness, feeling tired or weak, cough, and changes in color or sensation in the fingers and toes (Raynaud’s phenomenon).
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Call 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you: have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; have an autoimmune disease such as systemic lupus erythematosus, also known as lupus; are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby; are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
